← All trials
NCT04084678
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2019
- Primary completion
- Dec 15, 2022
- Completion date
- Dec 15, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 193
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- United TherapeuticsLead sponsor
- United TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.